Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation.
BACKGROUND
Microglial cell activation and cerebral function impairment are described in both chronic hepatitis C viral (HCV) and Human-Immune-Deficiency viral (HIV) infections. The aim of this study was to investigate the effect of acute HCV infection upon cerebral function and microglial cell activation in HIV-infected individuals.


METHODS
A case-control study was conducted. Subjects with acute HCV and chronic HIV coinfection (aHCV) were compared to matched controls with chronic HIV monoinfection (HIVmono). aHCV was defined as a new positive plasma HCV RNA within 12 months of a negative RNA test. Subjects underwent neuro-cognitive testing (NCT), cerebral proton magnetic resonance spectroscopy ((1)H-MRS) and positron emission tomography (PET) using a (11)C-radiolabeled ligand (PK11195), which is highly specific for translocator protein 18 kDA receptors on activated microglial cells. Differences between cases and controls were assessed using linear regression modelling.


RESULTS
Twenty-four aHCV cases completed NCT and (1)H-MRS, 8 underwent PET. Of 57 HIVmono controls completing NCT, 12 underwent (1)H-MRS and 8 PET. Subjects with aHCV demonstrated on NCT, significantly poorer executive function (mean (SD) error rate 26.50(17.87) versus 19.09(8.12), p = 0.001) and on (1)H-MRS increased myo-inositol/creatine ratios (mI/Cr, a marker of cerebral inflammation) in the basal ganglia (ratio of 0.71(0.22) versus 0.55(0.23), p = 0.03), compared to subjects with HIVmono. On PET imaging, no difference in (11)C-PK11195 binding potential (BP) was observed between study groups (p>0.10 all cerebral locations), however lower BPs were associated with combination antiretroviral therapy (cART) use in the parietal (p = 0.01) and frontal (p = 0.03) cerebral locations.


CONCLUSIONS
Poorer cognitive performance and disturbance of cerebral metabolites are observed in subjects with aHC,V compared to subjects with HIVmono. Higher (11)C-PK11195 BP was not observed in subjects with aHCV, but was observed in subjects not on cART.
Department of Medicine, Imperial College London, London, United Kingdom. lucy.garvey@nhs.net
Lucy J
LJ
Garvey
Nicola
N
Pavese
Anil
A
Ramlackhansingh
Emma
E
Thomson
Joanna M
JM
Allsop
Marios
M
Politis
Ranjababu
R
Kulasegaram
Janice
J
Main
David J
DJ
Brooks
Simon D
SD
Taylor-Robinson
Alan
A
Winston
D000208:Acute Disease; D000328:Adult; D001692:Biological Transport; D002250:Carbon Radioisotopes; D016022:Case-Control Studies; D002540:Cerebral Cortex / Q000378:metabolism / Q000503:physiopathology* / Q000821:virology; D002908:Chronic Disease; D003071:Cognition; D060085:Coinfection; D006678:HIV / Q000502:physiology*; D015658:HIV Infections / Q000378:metabolism / Q000503:physiopathology* / Q000821:virology; D016174:Hepacivirus / Q000502:physiology*; D006526:Hepatitis C / Q000378:metabolism / Q000503:physiopathology* / Q000821:virology; D006801:Humans; D007546:Isoquinolines / Q000378:metabolism; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D017628:Microglia / Q000378:metabolism* / Q000821:virology; D008875:Middle Aged; D009483:Neuropsychological Tests; D049268:Positron-Emission Tomography; D012367:RNA, Viral / Q000378:metabolism*
D002250:Carbon Radioisotopes; D007546:Isoquinolines; D012367:RNA, Viral; C037850:PK 11195